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Abstract 
Background: Hypertrophic cardiomyopathy (HCM) is a prevalent and complex cardiovascular 
condition. Despite being strongly associated with genetic alterations, wide variation of disease 
penetrance, expressivity and hallmarks of progression complicate treatment. We aimed to 
characterize different human isogenic cellular models of HCM bearing patient-relevant 
mutations to clarify genetic causation and disease mechanisms, hence facilitating the 
development of effective therapeutics. 
Methods: We directly compared the p.β-MHC-R453C and p.ACTC1-E99K HCM-associated 
mutations in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and 
their healthy isogenic counterparts, generated using CRISPR/Cas9 genome editing 
technology. By harnessing several state-of-the-art HCM phenotyping techniques, these 
mutations were investigated to identify similarities and differences in disease progression and 
hypertrophic signaling pathways, towards establishing potential targets for pharmacological 
treatment. CRISPR/Cas9 knock-in of the genetically-encoded calcium indicator R-GECO1.0 
to the AAVS1 locus into these disease models resulted in calcium reporter lines.  
Results: Confocal line scan analysis identified calcium transient arrhythmias and intracellular 
calcium overload in both models. The use of optogenetics and 2D/3D contractility assays 
revealed opposing phenotypes in the two mutations. Gene expression analysis highlighted 
upregulation of CALM1, CASQ2 and CAMK2D, and downregulation of IRF8 in p.β-MHC-
R453C mutants, whereas the opposite changes were detected in p.ACTC1-E99K mutants. 
Contrasting profiles of nuclear translocation of NFATc1 and MEF2 between the two HCM 
models suggest differential hypertrophic signaling pathway activation. Calcium transient 
abnormalities were rescued with combination of dantrolene and ranolazine, whilst 
mavacamten reduced the hyper-contractile phenotype of p.ACTC1-E99K hiPSC-CMs.  
Conclusions: Our data show that hypercontractility and molecular signaling within HCM are 
not uniform between different gene mutations, suggesting that a ‘one-size fits all’ treatment 
underestimates the complexity of the disease. Understanding where the similarities 
(arrhythmogenesis, bioenergetics) and differences (contractility, molecular profile) lie will allow 
development of therapeutics that are directed towards common mechanisms or tailored to 
each disease variant, hence providing effective patient-specific therapy.  
 
Keywords: hypertrophic cardiomyopathy; disease modeling; isogenic human pluripotent stem 
cell-derived cardiomyocytes; mechanistic insight; tailored therapeutics 
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1. Introduction  
Hypertrophic cardiomyopathy (HCM) is a prevalent cardiovascular disease which is the 
leading cause of sudden cardiac death in young adults, including athletes [1, 2]. Patients with 
HCM have a diverse clinical presentation, although thickening of the left ventricle detected by 
echocardiogram is commonly reported [3]. Other clinical manifestations include cardiomyocyte 
hypertrophy, myofibrillar disarray and left ventricular outflow tract (LVOT) obstruction [4]. 
Over 1400 mutations across over 25 genes have been associated with HCM progression, with 
the majority affecting sarcomeric proteins, which regulate cardiomyocyte contraction [5]. Of 
the sarcomeric genes involved, 20-50% of genotyped cases implicate MYH7, encoding for the 
beta myosin heavy chain (β-MHC) thick filament. A lower incidence (1-5%) involve ACTC1, 
encoding the alpha cardiac actin thin filament [6]. However, approximately half of HCM 
patients do not exhibit mutations in known sarcomeric genes [7], and while genetic lesions 
occur at 1:200 incidence, only 1:500 individuals develop HCM phenotypes [8]. Thus, with such 
an array of potentially causative mutations, HCM has variable penetrance, expressivity and 
severity [9], which greatly complicates treatment.  
Due to this phenotypic variability, various animal models, explanted heart biopsies and their 
derivatives, and in vitro cellular models have been developed to gain a deeper understanding 
of this complex disease. However, the investigation of different disease models has often led 
to conflicting results. The study of animals is hampered by species-differences in 
pathophysiology, whilst processed tissue typically involves demanding logistics and/or 
tendency towards technical artefacts [10]. Some models have linked sarcomeric mutations to 
higher myofilament calcium sensitivity [11, 12] and arrhythmias [13, 14]. Others have shown 
altered contractility but this varies from hypo- [15-17], to hyper-contractility [18-20]. It is now 
clear that HCM phenotypes are mutation-specific, and their detection and validation depends 
on the disease model under study and the existence of bonafide (isogenic) genetic controls 
[21], which were, until recent advances in gene-editing technology, challenging to obtain. 
Given this variability, we sought to directly compare two isogenic sets of HCM in 
physiologically-relevant human induced pluripotent stem cell-cardiomyocyte (hiPSC-CM) 
models. We have previously demonstrated the CRISPR/Cas9 generation of an isogenic trio 
of wild-type, heterozygote and homozygote hiPSCs harbouring the g.MYH7C9123T mutation, 
corresponding to the pathogenic protein change p.β-MHC-R453C [15]. In addition, we 
developed an isogenic duo of hiPSCs harbouring the c.ACTC1G301A mutation, also known as 
p.ACTC1-E99K [19]. These hiPSC-CMs models were focused on the validation of key HCM 
hallmarks (hypertrophy and activation of brain natriuretic peptide (BNP) pathway, sarcomeric 
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disarray and calcium sensitivity) and provided clarification of the genetic causation of this 
disease. 
Here, we extended these studies by performing parallel comparisons of the cellular and 
molecular features of these two in vitro hiPSC-CM models of HCM, to identify mutation-specific 
effects that could better inform clinicians on the most efficient therapeutic option. By utilizing 
state-of-the-art gene-edited isogenic controls and phenotyping technology [22], the molecular 
characterisation of refined cellular models of HCM enabled deeper understanding of 
mechanistic complexity and addressed the need for efficient therapy. 
 
2. Materials and methods  
Detailed methods are provided in the online Supplementary Materials. All patient skin biopsies 
were donated via informed consent under the approval of Research Ethics Committee - 
number 09/H0408/74. All data is presented as mean with standard deviation (SD) or box and 
whiskers plot, with the number of biological replicates indicated in the respective figure legend, 
performed in technical triplicates unless otherwise stated. Statistical analysis was performed 
using GraphPad software (v8.2). ACTC1MUT/WT was directly compared to ACTC1WT/WT hiPSC-
CMs using unpaired Student’s t-test. A one-way ANOVA with Newman-Keuls multiple 
comparison test was used for MYH7 isogenic trio data analysis, unless otherwise stated. Drug 
treatments were compared to vehicle controls using unpaired Student’s t-test. Significance 
tests were based on p-values as follows: * p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
   
3. Results  
3.1 Revisiting isogenic sets of ACTC1-mutant and MYH7-mutant hiPSCs generated by 
CRISPR/Cas9 editing 
In order to compare the effects of different sarcomeric mutations in HCM, we have utilized 
previously generated isogenic hiPSC-CM models, whereby CRISPR/Cas9 was used to either 
introduce the g.MYH7C9123T mutation in healthy hiPSCs or correct the c.ACTC1G301A variant in 
patient lines. In each case, a gRNA/Cas9-nickase/CRISPR strategy was used to introduce a 
drug selection cassette concurrently with the polymorphism of interest in the juxtaposed arm 
of homology. After confirmation of targeting, recombinase-mediated cassette excision was 
employed to create the isogenic sets [23], the fidelity of which were confirmed by PCR 
genotyping and sequencing. These five cell lines comprised a trio of wild-type (MYH7WT/WT), 
heterozygous (MYH7WT/MUT) and homozygous (MYH7MUT/MUT) mutants for the p.β-MHC-R453C 
change (Figure S1A-C) derived from a health line named REBL-PAT, and a duo of wild-type 
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(ACTC1WT/WT) and heterozygous (ACTC1WT/MUT) for the p.ACTC1-E99K change (Figure S1D-
F) originated from a heterozygous patient (E99K1) [19]. These isogenic sets validated the 
hypertrophic phenotype, as mutant hiPSC-cardiomyocytes displayed the main hallmarks of 
HCM such as increase in cell volume, activation of the hypertrophic BNP pathway and 
sarcomeric disarray [15, 19]. 
3.2 Generation of calcium reporter lines by CRISPR/Cas9 targeting of the AAVS1 safe 
harbor locus 
In order to assess the effect of each mutation on calcium transients, CRISPR/Cas9 was used 
to introduce the genetically-encoded calcium indicator (GECI) R-GECO1.0, into the genome 
of the five hiPSC lines. The safe harbour locus AAVS1 was targeted, interrupting the first intron 
of PPP1R12C (Figure 1A), which has been reported to be devoid of any adverse cellular 
effects [24]. A dual gRNA/Cas9-nickase/CRISPR approach was used to knock-in a cassette 
containing R-GECO1.0 driven by the CAG promoter, followed by a puromycin resistance gene. 
This cassette was flanked on each side with 1 kb of homology to the AAVS1 locus. 
Successful targeting of the AAVS1 locus was confirmed by PCR genotyping and sequencing 
in each of the five genetic backgrounds (Figure 1B-E). These hiPSC lines were successfully 
differentiated to hiPSC-CMs, and expression of R-GECO1.0 was verified by 
immunocytochemistry for α-actinin and RFP, with the latter antibody cross reacting with R-
GECO1.0 (Figure 1F). Despite the initially observed heterogeneity in the RGECO1.0 
expression between hiPSC-CM clones, due to transcriptional silencing upon differentiation (as 
recently reported [25]), we have minimized interline differences by choosing clones with 
comparable RGECO expression levels for phenotypic studies. Moreover, the use of a GECI 
ensured higher longevity of the calcium signal without increasing the background fluorescence 
over time (Figure S2A,B), and no cytotoxicity or signal diffusion (Figure S2C-E) relative to 
the commonly used Fluo-4 AM calcium dye. The reporter lines displayed comparable 
cardiomyocyte differentiation efficiencies at >90% (Figure S3A,B) and enabled calcium 
imaging by confocal line scans of single cardiomyocytes (Figures 1G, S3C), as an alternative 
to multicellular approaches based on the evaluation of rotor formation in cardiomyocyte 
monolayers labelled with calcium-dyes [26]. 
3.3. Confocal laser line scan analysis highlights calcium transient abnormalities in both 
ACTC1- and MYH7-mutant hiPSC-CMs 
Calcium transient abnormalities have been identified as a key phenotype of HCM [13], so we 
sought to assess this in both ACTC1 and MYH7-mutant hiPSC-CMs utilising the expression 
of R-GECO1.0. For this, hiPSCs were differentiated in a monolayer protocol [15], re-plated as 
single cells at day 15, and calcium transient analysis was performed at day 30, through rapid 
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laser line confocal microscopy at 1.8 mM Ca2+. Aberrant calcium transient events manifested 
as double peaks and/or partial peaks, and could be quantified using pClamp software. 
Frequency of aberrant events increased in accordance with mutation load by 4- to 10-fold for 
heterozygous and homozygous MYH7, respectively (Figure 2A-D), and 2.3-fold for 
heterozygous ACTC1 (Figure 2G-I). 
We hypothesised that these abnormal events indicated arrhythmias and occurred as a result 
of high cytosolic calcium levels. Therefore, the amplitude of the fluorescence signal-to-noise 
ratio (F/F0) was used as approximation to gain an insight into the levels of intracellular calcium. 
In both MYH7WT/MUT and MYH7MUT/MUT hiPSC-CMs, systolic calcium peak amplitude was 
significantly greater than the MYH7WT/WT isogenic control (Figure 2E). However, this was not 
recapitulated in ACTC1WT/MUT hiPSC-CMs (Figure 2J). In addition, we have measured the 
baseline RGECO fluorescence intensity (F0) as an approximation of the diastolic calcium 
levels in hiPSC-CMs. These showed that HCM lines displayed higher diastolic calcium 
reserves relative to their isogenic healthy lines, in both mutations (Figure S3D,E). Moreover, 
we assessed the sarcoplasmic reticulum (SR) Ca2+ storage capacity by analysing calcium 
transient activity upon treatment with 10mM caffeine, which induces Ca2+ release into the 
cytoplasm. This revealed similar SR Ca2+ release (RGECO ∆F/F0 peak intensity ratio) 
between HCM-mutant hiPSC-CMs and their healthy isogenic controls (Figure S3F-H). 
Other differences were also evident between MYH7 and ACTC1 mutants. Namely, while 
MYH7-mutant hiPSC-CMs displayed increased spontaneous beat rate relative to isogenic WT 
control (Figure 2F), the ACTC1 mutation did not cause significant changes in beat rate 
(Figure 2K). Taken together, these data showed that aberrant calcium transient events were 
a common feature between the gene mutations, but there were key differences in the response 
in systolic calcium peak amplitude and spontaneous beat rate for MYH7 relative to ACTC1 
mutants. 
3.4. Contractility analysis utilising 2D optogenetic pacing and 3D engineered heart 
tissue technology reveals opposing phenotypes between HCM models  
To provide a functional characterization of the two isogenic HCM model lines, contractility was 
assessed in both 2D and 3D formats. For 2D contractility analysis, hiPSC-CMs were first 
transiently transfected with a vector containing a CAG-ChR2-EYFP-T2A-BSD cassette, at an 
average efficiency across all five HCM lines of ~38% (Figure S4). Expression of 
channelrhodopsin-2 (ChR2) allowed hiPSC-CMs to be optically paced at 1 Hz with LED light, 
obviating the need for invasive electrode pacing. 
Contractility was assessed in 2D using the CellOPTIQ™ and pixel displacement algorithms  
[27] to estimate the cell shortening of the different hiPSC-CM lines. This revealed that, while 
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MYH7-mutant hiPSC-CMs displayed a hypo-contractile phenotype, ACTC1WT/MUT hiPSC-CMs 
exhibited hyper-contractility relative to their respective isogenic controls (Figure 3A-D), 
illustrating a key difference in phenotype between these two HCM-associated mutations. 
Analysis of contractile force was further performed using 3D human engineered heart tissues 
(hEHTs), which enable measurements of force generation by evaluating the movement of 
silicone posts attached to the tissue [28]. Changes in spontaneous beat rates follow the same 
trend as in the 2D platform, with only the MYH7-mutation increasing the spontaneous beating 
frequency (Figure S4E). Force generation at 2 Hz electrical pacing was measured in fibrin 
EHTs made with the different hiPSC-CM lines and corroborated the contrasting hypo- vs 
hyper-contractile phenotypes seen in MYH7 and ACTC1 mutants, respectively (Figure 3E-H). 
Interestingly, both mutations led to prolonged contraction and relaxation times in comparison 
to their isogenic controls (Figure 3I,J). 
3.5 Metabolic respiration profiles are similar in both HCM mutations 
To further evaluate the impact of the two HCM mutations, energy metabolism of the various 
lines was investigated using the SeaHorse XF Mito Stress Test assay, to assess mitochondrial 
respiration. In both isogenic sets of HCM models, presence of a sarcomeric mutation 
increased the oxygen consumption rate (OCR) during sequential addition of electron transport 
chain inhibitors (Figure 3K,L). Indeed, basal and maximal respirations increased significantly 
in both mutant sets (Figure 3M,N), supporting the energy depletion model [29] and indicating 
that inefficient energy metabolism is a phenotype shared by both mutants. 
3.6 Gene expression analysis uncovers potential molecular determinants underlying 
contrasting hypertrophic phenotypes  
In order to uncover disease mechanisms and identify new potential targets for phenotypic 
rescue of HCM, gene expression analysis was performed using qRT-PCR for selected ion 
channels, calcium handling pathways and hypertrophy-associated genes (Figure 4A,B).  
These analyses identified an upregulation of the late sodium channel SCN5A in both MYH7- 
and ACTC1-mutants relative to their respective isogenic controls, suggesting a compensatory 
response [30]. However, important differences were observed between the two hiPSC-CMs 
HCM models, with the calcium-binding proteins calmodulin-1 (CALM1), calsequestrin-2 
(CASQ2) and Ca2+/calmodulin-dependent kinase II (CAMK2D) being upregulated in MYH7-
mutants and downregulated in ACTC1-mutants. Furthermore, IRF8, a negative regulator of 
NFATc1 translocation to the nucleus that is associated to a pathological response [31], was 
downregulated in MYH7-mutants and upregulated in ACTC1-mutants.  
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In order to ascertain whether these gene expression changes were impacting on known 
hypertrophic signaling pathways, the nuclear translocation of NFATc1 [32] and MEF2C [33] 
were investigated by high-content imaging (Figure 4C-F). Remarkably, the two mutant lines 
showed a contrasting pattern: MYH7-mutant hiPSC-CMs exhibited an increase in the nuclear 
translocation of both transcription factors relative to the isogenic control, with the ACTC1 
mutants displaying the opposite response. 
3.7 Calcium sensitivity of ACTC1- or MYH7-mutant hiPSC-CM lines identifies potential 
therapeutic targets for HCM 
Despite showing similar arrhythmic responses to the sarcomeric mutations, the two HCM 
models differed considerably in expression levels of Ca2+-binding proteins. Therefore, and 
given that increased myofilament calcium sensitivity is often detected in HCM models [11, 13, 
34], we aimed to characterize the influence of extracellular Ca2+ in the arrhythmogenic 
phenotypes observed in isogenic hiPSC-CMs, via confocal line scanning. 
By increasing the extracellular Ca2+ from 1.8 to 3.0 mM, the frequency of arrhythmic events 
rose in all the cellular lines (Figure 5A,B). However, the decrease of extracellular Ca2+ to 0.1 
mM triggered different responses: arrhythmias were nearly abolished in both ACTC1 sets but 
this was only true in the homozygous variant of the MYH7-mutant hiPSC-CMs. The changes 
in arrhythmogenicity of the MYH7 lines were in line with the variation of calcium transient 
amplitude (Figure 5C). Altogether, these results indicated that, by limiting the amount of Ca2+ 
available for contraction, the arrhythmogenic phenotype could potentially be reversed in some 
sarcomeric mutant hiPSC-CMs.  
To further demonstrate that HCM hiPSC-CMs displayed perturbed calcium homeostasis 
underlying arrhythmogenic phenotypes, pharmacological antagonism of the L-type calcium 
channel by the addition of 1 µM nifedipine was performed during confocal laser line scan 
experiments. Both MYH7- and ACTC1-mutant hiPSC-CMs were capable of maintaining 
contraction upon 1 µM nifedipine addition, whereas the respective wild-type isogenic controls 
slowed or stopped beating altogether after L-type calcium channel blockade (Figure 5D-I), as 
expected [35].  
3.8 Rescue of arrhythmogenic phenotypes with pharmacological intervention  
High intracellular calcium, particularly during diastole, is known to induce arrhythmias and 
abnormal calcium transient events [36]. It can also drive the electrogenic Na+/Ca2+ exchanger 
(NCX), resulting in further inward flow of Na+ [37]. Given that cytosolic Ca2+ levels interfered 
with the magnitude of the arrhythmic phenotype, coupled with the transcriptomic changes in 
genes encoding sodium channel (SCN5A) and calcium-binding proteins, calcium handling 
pathways were targeted by pharmacological approaches. 
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Dantrolene is a ryanodine receptor antagonist that inhibits sarcoplasmic Ca2+ release into the 
cytosol [38], and thus attenuates cytosolic Ca2+ build-up in hiPSC-CMs upon depolarization. 
Treatment of HCM lines with 10 µM dantrolene resulted in a modest reduction in the 
arrhythmogenic events (Figure S5A,B), evaluated by confocal line scanning. 
Ranolazine is an enhancer of the outward mode of NCX, by blocking late sodium current and 
subsequently promoting intracellular Ca2+ efflux [37]. While this drug showed partial efficiency 
in isolated mouse cardiomyocytes [39], clinical trials have not demonstrated functional efficacy 
in HCM patients [37, 40]. Thus, a combination treatment of 10 µM dantrolene and 10 µM 
ranolazine was performed on the isogenic HCM hiPSC-CM lines. This strategy proved 
effective in reducing the frequency of arrhythmic events in heterozygous mutants 
(representative of HCM patient genotypes) to levels comparable to their respective isogenic 
healthy controls (Figure 6A-F).   
3.9 Targeting opposing HCM phenotypes with contractility modulators 
While both isogenic sets displayed similar arrhythmogenic phenotypes, changes in 
contractility were diametrically opposed, with MYH7-mutants displaying hypo-contractility and 
ACTC1-mutants exhibiting a hyper-contractile phenotype. 
Omecamtiv mecarbil (OM) prolongs the binding of myosin heads to actin by increasing the 
speed of ATP hydrolysis, thereby enhancing cardiac contractility [41], and is showing 
promising results in ongoing phase II clinical trials [42]. However, treatment of MYH7-mutant 
hiPSC-CM lines has not resulted in any functional reversal of the hypo-contractile phenotype 
shown (Figure S5C-J), as assessed by 2D pixel-displacement contractility measurements 
under 1Hz pacing.  
In contrast, mavacamten (also known as MYK-461) is a cardiac myosin ATPase inhibitor that 
counteracts hyper-contractility, as demonstrated in a mouse model of HCM [43], which 
translated in a reduction of LVOT obstruction and improved exercise capacity in patients [44]. 
Treatment of p.ACTC1-E99K hiPSC-CMs with 0.3 µM MYK-461 led to reversal of the hyper-
contractile phenotype towards the levels seen in the wild-type isogenic counterparts (Figure 
6G-K). 
Taken together, these approaches illustrate the complexity and phenotypic variability between 
the two HCM-associated mutations. Nonetheless, bespoke pharmacological intervention was 
able to ameliorate key phenotypes, with combination treatment successfully rescuing 
arrhythmogenicity in both models. 
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4. Discussion  
HCM is a prevalent and complex genetic disease, with highly variable clinical presentation and 
outcomes [3]. Due to the numerous mutations associated with this condition, phenotype 
severity, expressivity and penetrance differs greatly both within and between different genetic 
variants. Here, we described the phenotypic and mechanistic similarities and differences 
between two HCM-associated mutations - g.MYH7C9123T and c.ACTC1G301A, by comparing 
isogenic sets of hiPSC-CMs to provide physiologically-relevant in vitro models. The use of the 
isogenic approach minimizes the baseline variability of hiPSC-CMs features due to unrelated 
genetic backgrounds (as detected by changes in baseline contraction force in 3D hEHTs [15], 
or differences in the basal and maximal respiration levels between healthy lines). This 
approach allows focus to be centred on the influence of each mutation on disease progression 
[21]. While patients typically show heterozygous mutations in sarcomeric genes [45] 
(recaptured in the hiPSC-CM lines), the use of MYH7 homozygous-mutant lines for in vitro 
disease modeling provides extra readout sensitivity for the phenotypic assays developed.  
Moreover, by applying the same experimental conditions to all the lines in parallel, such as 
defined serum-free medium and pacing, the impact of underlying biological variability between 
isogenic lines (e.g., different beat rate) has been minimized [46]. 
We utilized the GECI R-GECO1.0 to image calcium transients in hiPSC-CMs and identified 
an association between aberrant events and mutation load in both isogenic sets. Commercially 
available calcium dyes typically exhibit gradual dye extrusion, which limits the time-frame of 
imaging experiments and may lead to experimental artefacts due to undesired 
compartmentalization in the endoplasmic reticulum [47]. In contrast, the use of a genetic 
calcium sensor provided experimental flexibility, and alleviated the problems of dye leakage 
and increased toxicity experienced when using traditional calcium indicator chemical dyes [48, 
49]. This GECI was inserted into the extensively studied safe locus AAVS1, whereby intronic 
disruption of the PPP1R12C gene has not reported to cause deleterious cellular effects [24]. 
Importantly, while an increase in diastolic calcium and overall intracellular calcium overload 
(as evidenced by response to nifedipine) was seen in both models, a higher systolic calcium 
peak amplitude was only observed in MYH7-mutant hiPSC-CMs. Interestingly, recent reports 
using cytoplasmic R-GECO1.0 to study the p.R92Q-cTnT and p.R145G-cTnI HCM-associated 
mutations found systolic peak amplitude changes in the latter model but not the in the former 
[50]. Thus, genetically-encoded calcium reporter cell lines are increasingly useful tools to 
investigate discrepancies of calcium transient abnormalities in HCM patients bearing different 
mutations [51]. Finally, both HCM models did not reveal differences in SR Ca2+ storage as 
sarcomeric mutant hiPSC-CMs showed similar responses to caffeine as healthy lines. These 
data are further supported by the lack of changes in expression of genes involved in SR Ca2+ 
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release (TRDN, PLN) or re-uptake (SERCA2A). Remarkably, this response contrasts with the 
p.R442-βMHC hiPSC-CMs that showed depressed SR Ca2+ storage which is accompanied by 
downregulation of SERCA2A and RYR2 [13], further strengthening the notion that HCM effects 
are mutation-specific. 
One of the most striking differences between the p.β-MHC-R453C and p.ACTC1-E99K hiPSC-
CM models was altered contractility. g.MYH7C9123T mutants exhibited hypo-contractility, which 
contrasts to the hyper-contractility phenotype reported in C2C12 murine myoblasts forced to 
overexpress recombinant β–MHC with the same mutation [18]. This highlights potential 
species-differences, particularly in terms of isoform expression, as rodent hearts exhibit 
different ventricular predominance of α vs β-MHC expression relative to humans [52, 53]. 
Nevertheless, even in other hiPSC-CM models, the p.β–MHC-E848G mutation was found to 
be hypo-contractile [17], whilst the p.β–MHC-R403Q mutation was found to be hyper-
contractile [20]. Altogether, the assertion that all thick filament mutations behave similarly must 
be challenged. Importantly, our data is in line with direct myofilament evaluation studies 
performed in human cardiomyocytes bearing several MYH7 mutations, whereby a loss in 
maximal contraction force is not accompanied by changes in Ca2+ sensitivity [16]. In contrast, 
p.ACTC1-E99K mutant hiPSC-CMs revealed hyper-contractility. This tallies with existing 
mouse models of this mutation, which show a 3-4-fold greater force generation compared to 
a non-transgenic control [54]. Notably, both mutations caused a similar increase in both 
contraction and relaxation times, detected in 3D hEHTs. 
The energy depletion model, which states that sarcomere mutations cause inefficient ATP 
usage, thereby increasing the energetic demand on cardiomyocytes, is regarded as the main 
source of myocardial energy deficiency [29]. This often results in sudden cardiac death 
particularly in athletes, where a fast-beating heart necessitates even more energy. We have 
observed a greater mitochondrial respiration rate in diseased lines relative to their isogenic 
healthy controls, which is characteristic of the compensatory stage of HCM that precedes 
energy depletion. Thus, we postulate that this inefficient ATP usage impinges on the ability of 
SERCA2A (whose expression levels are unaltered relative to healthy isogenic controls, 
indicating a lack of compensation) to pump Ca2+ back into the sarcoplasmic reticulum during 
diastole. This in turn leads to high intracellular calcium and triggered aftercontractions, 
detected as calcium transient abnormalities [13, 36].  
Calcium is known to play a key role in hypertrophic signaling, via calcineurin-mediated 
activation of NFATc1 [32] and MEF2C [33], resulting in their translocation to the nucleus where 
hypertrophic gene pathways (e.g., fetal gene program [55]) are initiated. Despite converging 
on calcium transient disruption as a key hallmark of HCM progression (leading to the observed 
arrhythmias and prolonged beating upon nifedipine treatment), the two models differ greatly 
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in the expression of Ca2+-binding proteins and subsequent hypertrophic transcription factor 
activation. Remarkably, MYH7-mutant hiPSC-CMs displayed up-regulation of CALM1, 
CASQ2 and CAMK2D relative to their healthy isogenic controls, and a reduction in expression 
of IRF8 (a negative regulator of NFATc1 nuclear translocation [31]), with the opposite being 
shown in ACTC1-mutants. This led to contrasting profiles of nuclear translocation of NFATc1 
and MEF2 between the two isogenic sets. We reason that the transcriptomic discrepancies 
between the two HCM models underlie this difference, as by controlling the levels of 
calsequestrin [56], calmodulin [57] and consequently intracellular Ca2+ available, the activation 
of transcription factors like IRF8, NFATc1 and MEF2 is affected, affecting downstream 
hypertrophic pathways (Figure 7). Moreover, elevated Ca2+/calmodulin-dependent kinase II 
(CAMK2D) activity has shown to trigger arrhythmogenesis by phosphorylating ryanodine 
receptor, which leads to increased SR Ca2+ release [58, 59]. CAMK2D also promotes MEF2 
translocation to the nucleus by phosphorylating the MEF repressor HDAC4, promoting its 
nuclear export [60]. Importantly, the up-regulation of CAMK2D in MYH7-mutant hiPSC-CMs 
is in line with the higher levels of cytosolic Ca2+ detected, and increased nuclear translocation 
of MEF2 in these cells, with the ACTC1-mutant cardiomyocytes showing a consistently 
opposite profile.  
We speculate that these transcriptomic changes are akin to gene modifiers that contribute to 
the magnitude of the HCM phenotypes elicited by the primary sarcomeric mutation [61]. The 
c.ACTC1G301A variant is particularly interesting in that individuals with the same mutation often 
display a wide variety of phenotypic severity [62, 63]. Indeed, our own studies on a family 
harbouring this mutation showed differences in clinical and phenotypic features, depending 
on the individual under study [19]. These differences could be the result of a myriad of factors 
including age, expression of disease-modifying genes, epigenetics modifiers, miRNAs and 
lncRNAs [61, 64]. The use of large-scale transcriptomic analyses from isogenic sets of hiPSC-
CMs [65] may uncover new drug targets, including gene modifiers who remain unexplored. 
Nevertheless, we harnessed the mechanistic data generated to guide pharmacological 
intervention strategies. In order to counter the elevated concentration of intracellular Ca2+, 
dantrolene was the drug of choice due to its success in rescuing aberrant Ca2+ leakage in a 
mouse model of troponin-T HCM, by stabilizing Ca2+ release from hyper-phosphorylated 
ryanodine receptors [66]. However, in both HCM hiPSC-CM models, the anti-arrhythmogenic 
effect of dantrolene was mild. Importantly, SCN5A was upregulated in both sarcomeric 
mutants, in comparison to their respective isogenic controls. This may be a compensatory 
mechanism for irregular NCX activity, or as a result of phosphorylation by CaMKIIδc [67]. 
Nonetheless, this increased SCN5A expression has also been observed in a hiPSC-CM model 
of c.MYH7C1324G mutation [13]. We therefore chose ranolazine as a late sodium channel 
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antagonist, a drug which has been shown to reverse NCX dysfunction and reduce the 
occurrence of delayed afterdepolarisations that occurred in a range of human ex vivo HCM 
heart samples [37]. As ranolazine failed to show full clinical efficacy [40], we combined it with 
dantrolene, resulting in the abrogation of the arrhythmogenic phenotype of heterozygous 
mutant HCM hiPSC-CMs, in both models.  
Contractility measurements based on pixel displacement of hiPSC-CM monolayers 
corroborated the phenotypes shown in more physiologically-relevant 3D hEHTs. Thus, we 
used the 2D format to test the effect of several compounds, due to its higher throughput and 
lower cell requirement [68]. These modulators of contractility displayed a mixed success, with 
mavacamten restoring the hyper-contractile phenotype of ACTC1-mutant hiPSC-CMs, but OM 
lacking functional recovery of hypo-contractility shown by MYH7-mutant cardiomyocytes. It is 
worth noting that the effects of OM are dependent on cytosolic Ca2+ levels, enhancing 
contractile force at lower concentrations, with the opposite effect at higher ones, as reported 
in skinned cardiomyocytes [69]. Given the observed increase in intracellular Ca2+ in MYH7-
mutant lines, it is thus likely that OM is favouring a reduction in contractility, thus failing to 
rescue the phenotype. Alternatively, the high pacing applied (required due to intrinsically high 
beat rates of hiPSC-CMs) may mask the positive inotropic effects of OM. Translating the 
success demonstrated by mavacamten to hEHT format is the goal of future focused studies, 
incorporating several hypercontractile-causing HCM mutations. Moreover, while further insight 
may be gained by inferring causality from the pharmacological treatment across phenotypes, 
these experiments are technically very challenging, e.g., due to differences in time scale 
between direct drug effects and indirect molecular signaling pathways or cellular responses. 
This will require further optimization across several orders of magnitude of drug concentrations 
and/or adaptation of existing phenotypic platforms [27]. 
In conclusion, we show that sarcomeric mutations leading to HCM can vary greatly in 
phenotype and mechanism. Each genetic variant must therefore be evaluated individually in 
order to identify more effective treatments. Our results indicate that future in vitro, mechanistic-
driven drug screens may benefit from combinatorial drug treatments to relieve mutation-
specific phenotypes.  
Limitations 
HiPSC-CMs are known to be immature in terms of ion expression, sarcomere alignment and 
other ultrastructural differences, relative to adult cardiomyocytes [68, 70]. These factors may 
impact the phenotypes of the disease models studied. Several maturation strategies under 
development are aimed at improving maturation by several approaches including chronic 
pacing [71] and biochemical cues [72]. Expectedly, this will generate more robust disease 
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models to study human cardiac disease in vitro. Nevertheless, it is reassuring that the 
outcomes in our data were consistent between 2D and 3D (despite the relatively low number 
of biological replicates performed in the latter format), with hiPSC-CMs fabricated into hEHTs 
known to be of a higher maturity status [73]. Overall, while hiPSC-CMs do not fully represent 
the complex architecture, multicellularity and neuro-hormonal control of the adult heart, they 
can be used to model genetically-complex diseases such as HCM in order to uncover new 
mechanistic information that drives the further development of efficient therapies, as shown 
herein. 
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Figure Legends 
Figure 1 - Generation of GECI lines by CRISPR/Cas9 targeting of the AAVS1 safe harbor 
locus. A) CRISPR/Cas9 nickase strategy was used to knock-in a CAG-driven R-GECO 
cassette in an intron of the AAVS1 locus in hiPSC-CM lines. B,C) PCR-genotyping confirms 
insertion of the R-GECO cassette in the AAVS1 locus of g.MYH7C9123T and c.ACTC1G301A HCM 
lines and their isogenic controls (correct product sizes indicated). D,E) Correct gene-editing 
was verified by Sanger sequencing the junctions between left and right arms of homology with 
the respective cassette ends. F) Representative fluorescence micrographs illustrating 
expression of R-GECO (green) in all the generated hiPSC-CM (red) lines (scale bar = 50µm). 
G) Confocal line scans were used to perform calcium imaging in hiPSC-CMs, by measuring 
the fluorescence intensity in the delineated region, in a single cell. TV, Targeting Vector; MW, 
molecular weight; NTC, non-template control; UNT, untargeted; WT, wild-type; MUT, mutant. 
Figure 2 – Calcium transient analysis underlying arrhythmias in HCM hiPSC-CM lines. 
A-C) Confocal line scanning of g.MYH7C9123T isogenic trio highlighted abnormal calcium 
transient events (golden arrows). D) Mean frequency of arrhythmic events increased from 
1.13% in MYH7WT/WT hiPSC-CMs to 4.33% in heterozygous MYH7C9123T mutants and 11.20% 
in the isogenic homozygous line. MYH7-mutant hiPSC-CMs exhibited: E) higher amplitude of 
calcium signal relative to isogenic WT control, suggesting an elevated systolic calcium peak 
(~2-fold higher in the heterozygous line, ~2.6-fold-higher in the homozygous line), and F) 
faster beat rate (average 21 bpm for WT, 44 bpm for heterozygous mutant and 41 bpm for 
homozygous mutant cardiomyocytes). G-I) The c.ACTC1G301A mutant hiPSC-CMs also 
displayed aberrant calcium transients (15.7% vs 6.7% in isogenic healthy control), with J) no 
significant changes in Ca2+ signal amplitude and K) beat rate, relative to isogenic WT control. 
Data: mean±SD, number of technical replicates indicated in respective bars in E and J, one-
way ANOVA + Newman-Keuls correction for multiple comparisons in MYH7 isogenic trio (D-
F: N=6-8 independent biological replicates) and unpaired t-test between ACTC1 lines (I-K: 
N=3-4 independent biological replicates), *p<0.05, ***p<0.001, ****p<0.0001. 
Figure 3 – Functional phenotyping of contractility and metabolism of HCM hiPSC-CMs. 
A) Micrograph showing pixel displacement of monolayer of hiPSC-CMs, which enables 
estimation of contractility in 2D by CellOPTIQ® technology. B,C) Representative traces of 
optically-paced (1 Hz) ChR2+ cardiomyocytes highlight a hypo-contractile phenotype in 
g.MYH7C9123T mutants and hyper-contractility in c.ACTC1G301A variants. D) Peak amplitude 
quantification revealed that MYH7WT/MUT and MYH7MUT/MUT hiPSC-CMs displayed a reduction 
in contractility relative to the isogenic WT control by ~32% and ~53%, respectively (N=5 
independent biological replicates), whereas ACTC1-mutant hiPSC-CMs exhibited ~41% 
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higher amplitude relative to its isogenic control (N=3 independent biological replicates). E) 
Fibrin-based human engineered heart tissue (hEHT) attached to silicon posts (scale bar = 1 
mm). F,G) Average contraction peaks of hEHTs made from the different HCM isogenic sets, 
electrically paced at 2Hz. H) hEHTs showed mean contraction forces of 0.070 mN in 
MYH7WT/WT, reducing to 0.053 mN in MYH7WT/MUT, and 0.037 mN in MYH7MUT/MUT hiPSC-CMs 
(N=4-7 independent biological replicates); ACTC1WT/WT hEHTs produced mean forces of 0.050 
mN, which increased to 0.080 mN in the ACTC1WT/MUT genotype (N=3-11 independent 
biological replicates).  I,J) Both isogenic sets of mutant EHTs showed significantly prolonged 
contraction and relaxation times in comparison to their respective isogenic controls.  K,L) 
Mitochondrial respiration profiles of both sets of HCM mutants, displaying a higher oxygen 
consumption rate (OCR) relative to their healthy isogenic counterparts. M) Basal respiration 
rate was higher in MYH7WT/MUT (~52% increase) and MYH7MUT/MUT (~20%) when compared to 
WT control (N=12 independent biological replicates), which was also verified in ACTC1 
mutants (~2.6-fold increase vs isogenic WT, N=9 independent biological replicates). N) 
Maximal respiration rate accompanied the increasing trend with the mutation load (~35% 
higher in heterozygous and ~43% higher in homozygous MYH7-mutants relative to isogenic 
WT control; ~93% increase in ACTC1 mutants vs isogenic WT control). Data: mean±SD, one-
way ANOVA + Newman-Keuls correction for multiple comparisons in MYH7 isogenic trio and 
unpaired t-test between ACTC1 lines, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
Figure 4 – Molecular analysis of calcium handling and hypertrophic pathways activated 
in HCM hiPSC-CM lines. qRT-PCR analysis of expression of Na+ and Ca2+ ion channels,  
Ca2+ handling pathways, and their regulators in A) MYH7-mutant lines (N=5-7 biological 
replicates) and B) ACTC1-mutant hiPSC-CMs (N=4-6 biological replicates) showed similar 
upregulation of SCN5A in both isogenic collections (~2.6-fold higher in MYH7-mutants, ~2.2-
fold higher in ACTC1-hiPSC-CMs), relative to their respective isogenic WT controls. This also 
revealed contrasting changes in the expression of Ca2+-binding proteins (CALM1: ~1.6-2.7-
fold higher in MYH7-mutants, ~50% lower in ACTC1-mutants; CASQ2: ~6-7-fold higher in 
MYH7-mutants, ~65% reduced in ACTC1-mutants; CAMK2D: ~31-91% higher in MYH7-
mutants, ~46% lower in ACTC1-mutants vs respective isogenic controls), and IRF8 (~40-50% 
reduced in MYH7-mutants, ~4.3-fold higher in ACTC1-mutants vs respective isogenic 
controls). C) Representative fluorescence micrographs highlighting nuclear translocation of 
NFATc1 and D) MEF2 in hiPSC-CMs bearing different genotypes (detailed in respective 
insets, nuclear-localized transcription factors highlighted by yellow arrows). E) Quantification 
of translocation of NFATc1 and F) MEF2 shows increase in the proportion of MYH7-mutant 
hiPSC-CMs displaying nuclear localisation (NFATc1: 2.3-fold higher in WT/MUT and 5.3-fold 
higher in MUT/MUT; MEF2:  3-fold-higher in homozygous mutant g.MYH7C9123T, relative to the 
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isogenic healthy control. N=6 biological replicates). The opposite response was seen in 
heterozygous ACTC1 mutants (NFATc1: 37% decrease in nuclear localisation; MEF2: 54% 
reduction, relative to WT isogenic control, N=9-12 biological replicates). Data: mean±SD, one-
way ANOVA + Newman-Keuls correction for multiple comparisons in MYH7 isogenic trio and 
unpaired t-test between ACTC1 lines, *p<0.05,**p<0.01, ***p<0.001, ****p<0.0001. 
Figure 5 – Calcium sensitivity responses of HCM hiPSC-CM lines. Confocal line scanning 
of A) g.MYH7C9123T isogenic trio and B) c.ACTC1G301A mutant vs isogenic healthy hiPSC-CMs 
exposed to varying concentrations of extracellular Ca2+ (N=3-5 biological replicates) showed 
that the arrhythmogenic phenotype is exacerbated by higher concentration of Ca2+ in the 
medium (3 mM) in all genotypes (~2-4-fold higher frequency of abnormal events in MYH7-
mutant lines; ~3-6-fold increase in ACTC1-mutant hiPSC-CMs). A reduction in the 
extracellular Ca2+ to 0.1 mM reversed this effect in ACTC1-mutant lines and in the 
homozygous g.MYH7C9123T variant. C) Changes in the frequency of arrhythmogenic events 
were in line with variations of amplitude in MYH7-mutant hiPSC-CMs. D-I) Treatment with 1µM 
Nifedipine caused fast cessation of beating in healthy hiPSC-CM lines (black bracket) whereas 
HCM cells (red bracket) maintained calcium transients for longer (% calcium transient peaks 
detected after 300 s treatment relative to baseline of 26.1% in MYH7WT/WT vs 78.6% in 
MYH7MUT/WT and 72.8% in MYH7MUT/MUT, N=5 biological replicates; 0% in ACTCWT/WT vs 49.3% 
in ACTCWT/MUT, N=3 biological replicates. Data: mean ±SD, number of technical replicates 
indicated in respective bars in C, one-way ANOVA + Newman-Keuls correction for multiple 
comparisons in MYH7 isogenic trio and unpaired t-test between ACTC1 lines, 
*p<0.05,**p<0.01, ***p<0.001, ****p<0.0001. 
Figure 6 – Pharmacological intervention strategies to rescue HCM phenotypes. 
Representative confocal line scans of heterozygote g.MYH7C9123T hiPSC-CMs treated with A) 
0.1% (v/v) DMSO (vehicle control) or B) 10 µM dantrolene + 10 µM ranolazine, with C,D) 
referring to c.ACTC1G301A hiPSC-CMs in the same respective order. E) Quantification of 
aberrant calcium transients (golden arrows) in MYH7 isogenic trio showed reduction of 
frequency of arrhythmogenic events in heterozygote mutants back to healthy control upon 
treatment with dantrolene + ranolazine (2.9-fold decrease relative to vehicle control, N=7-20 
biological replicates). F) The combination treatment also reduced the frequency of abnormal 
calcium transients in ACTC1WT/MUT to levels similar to healthy isogenic control (3-fold reduction 
vs vehicle control, N=10-12 biological replicates). Representative contractility traces of 
optically-paced (1Hz) ChR2+ c.ACTC1G301A hiPSC-CMs treated with G) 0.1% (v/v) DMSO 
(vehicle control), H) 0.3 µM MYK-461 and I) 1 µM MYK-461, relative to J) WT isogenic control. 
K) Quantification of contractility in 2D CellOPTIQ™ shows that treatment with MYK-461 
rescues hyper-contractile phenotype of ACTC1-mutant hiPSC-CMs back to isogenic healthy 
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levels (35-57% decrease in contractility relative to vehicle control, N=8 biological replicates). 
Data: box and whisker plots or mean ±SD, drug treatments were compared to vehicle controls 
using unpaired Student’s t-test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
Figure 7 – Mutation-specific disease mechanisms and pharmacological rescue of HCM. 
Both hiPSC-CM models shared upregulation of SCN5A and energy depletion as HCM 
mechanisms, which may impair Ca2+ re-uptake into the sarcoplasmic reticulum (SR) and 
precipitate arrhythmias. The R453C-βMHC model showed up-regulation of CASQ2, CALM1 
and CAMK2D and increased cytosolic Ca2+ levels, which further contribute to the 
arrhythmogenic phenotype. IRF8 was downregulated, promoting MEF and NFATc1 nuclear 
translocation to trigger hypertrophic response. Contrastingly, the E99K-ACTC1 model showed 
the opposite gene expression profile. The arrhythmogenic phenotype was rescued in both 
models by combination treatment with ranolazine and dantrolene. The hypercontractility 
displayed in E99K-ACTC1 cardiomyocytes was rescued by mavacamten. SR, Sarcoplamic 
reticulum; RYR2 – Ryanodine receptor; NCX, sodium-calcium exchange pump; SCN5A – 
sodium channel; CASQ2 – calsequestrin; CALM1 – calmodulin; CAMK2D - Ca2+/calmodulin-
dependent kinase II. 
  
Jo
urn
al 
Pr
e-p
ro
f
Journal Pre-proof
23 
 
Highlights 
 Isogenic models of hiPSC-CMs bearing sarcomeric mutations address HCM 
complexity. 
 Calcium reporter lines and optogenetics enabled refined phenotypic analyses 
of HCM. 
 Different mutations showed phenotypic and mechanistic similarities and 
differences. 
 Arrhythmias in both models were rescued by combining ranolazine and 
dantrolene. 
 Variable phenotypes support mechanism-driven development of effective 
therapeutics.  
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